trending Market Intelligence /marketintelligence/en/news-insights/trending/ulTvrCfPOGF9FHiNPGY1Jg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Lilly's Taltz performs better than J&J's Tremfya in head-to-head study

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Lilly's Taltz performs better than J&J's Tremfya in head-to-head study

Eli Lilly and Co.'s Taltz performed better than Janssen Biotech Inc.'s Tremfya in clearing the skin of patients with moderate to severe plaque psoriasis during a head-to-head clinical trial.

Psoriasis is an inflammatory autoimmune condition characterized by patches of abnormal skin on the body.

The phase 4 trial called IXORA-R met its primary goal, with a larger proportion of patients using Taltz seeing completely clear skin after 12 weeks compared to those using Tremfya.

The U.S. Food and Drug Administration has already approved Lilly's Taltz injection to treat adults with active psoriatic arthritis as well as moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The drug in a phase 3b trial also reduced sexual difficulties caused by genital psoriasis, prompting a label update approval from the FDA.

Janssen Biotech is a unit of Johnson & Johnson.